Please provide your email address to receive an email when new articles are posted on . Combination azilsartan medoxomil and chlorthalidone was shown to be superior to combination olmesartan medoxomil ...
The ESH-ESC guidelines do not provide recommendations on the individual members of drug classes, but recently a meta-analysis of ambulatory BP studies involving ARBs has shown that the drug used and ...
Blood pressure reductions statistically superior to olmesartan medoxomil-hydrochlorothiazide June 19, 2012 Results of a 12-week, head-to-head, phase 3 study published online in the American Heart ...
Of 52 subjects screened, 24 normotensive individuals (mean systolic and diastolic BPs 129.4 ± 7.5 and 75.2 ± 6.0mm Hg, respectively) were enrolled in the study and randomised to treatment. Of these, ...
May 24, 2011 (New York, New York) — The use of the combination therapy azilsartan medoxomil (Edarbi, Takeda Pharmaceuticals) and chlorthalidone resulted in a more effective reduction in systolic blood ...
A prespecified subgroup analysis of a 44-week open-label extension study is presented. The efficacy and safety of the combination of amlodipine (AML)+ olmesartan medoxomil (OM), with and without the ...
Parsippany, NJ (May 27, 2005) – Data from two clinical studies presented at the American Society of Hypertension's Twentieth Annual Scientific Meeting (ASH 2005) in San Francisco demonstrated that ...
Parsippany, NJ (May 26, 2004) – New data from two different clinical studies demonstrated that patients with hypertension can achieve more aggressive blood pressure goal rates using antihypertensive ...
This leaflet answers some common questions about OLAMLO HCT. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results